ArticleJournal of clinical medicine2022
Seven COVID-19 Patients Treated with C-Reactive Protein (CRP) Apheresis.
Article in Journal of clinical medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 20 citations in OpenAlex.
- Evaluating the clinical significance of tumor-expressed C-reactive protein in chromophobe renal cell carcinoma.Scientific reports · 2026Article
- Selective C-reactive protein apheresis in acute myocardial infarction: rationale and design of a prospective international randomized controlled trial.Coronary artery disease · 2025Article
- Association of high-sensitivity C-reactive protein with hepatic fibrosis in patients with metabolic dysfunction-associated steatotic liver disease.Frontiers in immunology · 2025Article
- Case Report: C-reactive protein apheresis in non-ST-elevation ACS-case series from the C-reactive protein apheresis in Acute Myocardial Infarction Registry.Frontiers in cardiovascular medicine · 2024Article
- The Potential Role of C-Reactive Protein in Metabolic-Dysfunction-Associated Fatty Liver Disease and Aging.Biomedicines · 2023Review
- Being Eaten Alive: How Energy-Deprived Cells Are Disposed of, Mediated by C-Reactive Protein-Including a Treatment Option.Biomedicines · 2023Article
- Assessing serum C-reactive protein as a predictor of COVID-19 outcomes: a retrospective cross-sectional study.Annals of medicine and surgery (2012) · 2023Article
- Prognostic Role of Monocyte Distribution Width, CRP, Procalcitonin and Lactate as Sepsis Biomarkers in Critically Ill COVID-19 Patients.Journal of clinical medicine · 2023Article
- A novel phosphocholine-mimetic inhibits a pro-inflammatory conformational change in C-reactive protein.EMBO molecular medicine · 2023Article
- C-reactive protein: a target for therapy to reduce inflammation.Frontiers in immunology · 2023Review
- Host-Directed Therapies for Tuberculosis.Pathogens (Basel, Switzerland) · 2022Review
- C-Reactive protein role in assessing COVID-19 deceased geriatrics and survivors of severe and critical illness.World journal of clinical cases · 2022Article
- A Real Pandora's Box in Pandemic Times: A Narrative Review on the Acute Cardiac Injury Due to COVID-19.Life (Basel, Switzerland) · 2022Review
- Special Issue "C-Reactive Protein and Cardiovascular Disease: Clinical Aspects".Journal of clinical medicine · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The fulminant course of COVID-19, triggered by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), presents with a high mortality rate and still lacks a causative treatment. C-reactive protein (CRP) has been shown to increase dramatically during the disease progression and correlates with deleterious outcomes. Selective CRP apheresis can reduce circulating CRP levels fast and effective. Methods: Seven hospitalized patients with documented severe COVID-19 progression, elevated CRP plasma levels (>100 mg/L) and signs of respiratory failure were treated with CRP apheresis. Two to twelve CRP apheresis sessions were performed generally in 24 h time intervals and depending on CRP plasma levels. Results: All patients had comorbidities. CRP apheresis reduced CRP plasma levels by up to 84% within a few hours, without exhibiting side effects in any patient. Despite signs of severe lung infiltration in all patients, only one patient died. The other patients showed improvements within the chest X-ray after CRP apheresis and were able to recover regardless of intubation and/or ECMO (4 patients). All remaining six patients were discharged from the hospital in good clinical condition. Conclusions: This case series presents a mortality rate of only 14%, which is dramatically lower than expected from the presented CRP levels as well as comorbidities and ventilation requirements. Our clinical observations regarding the here presented seven patients support the hypothesis that CRP is a candidate to be therapeutically targeted in the early stage of severe COVID-19.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.